Know Who's Eligible for New COVID-19 Monoclonal Antibodies
January 2021
Bamlanivimab and casirivimab/imdevimab will be the first meds authorized to treat OUTPATIENTS with COVID-19.
These new monoclonal antibodies block SARS-CoV-2 from entering cells. Both meds are single-dose IV infusions given over 1 hour.
You may be giving these "mabs" in your infusion center or a pop-up site (tent, etc). They're also being administered in long-term care facilities or even patients' homes.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote